Business Description
Acrivon Therapeutics Inc
NAICS : 541713
SIC : 2833
ISIN : US0048901096
Description
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 27.45 | |||||
| Equity-to-Asset | 0.88 | |||||
| Debt-to-Equity | 0.04 | |||||
| Debt-to-EBITDA | -0.07 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -130.9 | |||||
| 3-Year EPS without NRI Growth Rate | -88.1 | |||||
| 3-Year FCF Growth Rate | -108.7 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 41.01 | |||||
| 9-Day RSI | 46.43 | |||||
| 14-Day RSI | 50.45 | |||||
| 6-1 Month Momentum % | 24.35 | |||||
| 12-1 Month Momentum % | -46.69 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 9.75 | |||||
| Quick Ratio | 9.75 | |||||
| Cash Ratio | 9.58 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -20.5 | |||||
| Shareholder Yield % | 0.21 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -40.83 | |||||
| ROA % | -37.7 | |||||
| ROIC % | -249.92 | |||||
| ROC (Joel Greenblatt) % | -990.04 | |||||
| ROCE % | -44.2 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 1.63 | |||||
| Price-to-Tangible-Book | 1.63 | |||||
| EV-to-EBIT | -2.12 | |||||
| EV-to-Forward-EBIT | -1.52 | |||||
| EV-to-EBITDA | -2.14 | |||||
| EV-to-FCF | -2.98 | |||||
| Price-to-Net-Current-Asset-Value | 1.75 | |||||
| Price-to-Net-Cash | 1.78 | |||||
| Earnings Yield (Greenblatt) % | -47.17 | |||||
| FCF Yield % | -16.27 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers